Enlivex Therapeutics ((ENLV)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Enlivex Therapeutics recently updated its clinical study on Allocetra-OTS, a Phase 2 trial aimed at evaluating the efficacy, safety, and tolerability of different doses and regimens of Allocetra-OTS for treating organ failure in adult sepsis patients. This study is significant as it explores a novel treatment approach for a critical condition.
Allocetra-OTS is an innovative cell-based therapy designed to reprogram macrophages into their homeostatic state, potentially improving outcomes for sepsis patients. The treatment involves intravenous doses of modified allogeneic peripheral blood mononuclear cells.
The study was interventional, randomized, and placebo-controlled, with a parallel assignment model and double masking. Its primary purpose was treatment-focused, comparing different dosing regimens of Allocetra-OTS against a placebo.
The study began on November 30, 2020, and was completed with the last update submitted on August 18, 2025. These dates are crucial as they mark the progression and finalization of the trial, providing a timeline for potential market entry.
The completion of this study could positively influence Enlivex Therapeutics’ stock performance, as successful results may enhance investor confidence and position the company favorably against competitors in the sepsis treatment market.
The study is now completed, with further details available on the ClinicalTrials portal.